Institutional & Insider Ownership
17.3% of Avenue Therapeutics shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Endonovo Therapeutics and Avenue Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Endonovo Therapeutics | -6,075.54% | N/A | -279.35% |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
Earnings and Valuation
This table compares Endonovo Therapeutics and Avenue Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Endonovo Therapeutics | $170,000.00 | 0.00 | -$400,000.00 | ($10.00) | N/A |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | $0.76 | 0.20 |
Endonovo Therapeutics has higher revenue and earnings than Avenue Therapeutics. Endonovo Therapeutics is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Endonovo Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Receive News & Ratings for Endonovo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endonovo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
